MEDICINA
Departamento
Medical College of Wisconsin
Milwaukee, Estados UnidosPublicaciones en colaboración con investigadores/as de Medical College of Wisconsin (16)
2024
-
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
Dermatology and Therapy, Vol. 14, Núm. 3, pp. 593-612
2023
-
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 659-666
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
2022
-
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors
American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884
-
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893
2018
-
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
Leukemia, Vol. 32, Núm. 9, pp. 2032-2036
-
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598
2017
-
Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
Haematologica, Vol. 102, Núm. 10, pp. 1767-1775
-
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051